H.B. Fuller Nears £628 Million Deal for UK Medtech AMS
THE SO WHAT
H.B. Fuller paying roughly £628 million for Advanced Medical Solutions is a vertical integration move—owning tissue-healing products tightens control over a specialized medtech niche. If you're a mid-cap with differentiated IP in regulated healthcare, this is another signal that strategic buyers, not IPOs, may be your most realistic liquidity path.
READ THE SOURCE
MORE FROM THE WIRE
Startups & VenturePermira-Backed Womenswear Retailer Reformation Files for US IPO
Reformation filing for a US IPO with a sustainability narrative shows public markets will still underwrite focused, brand-led retail if unit economics are there. For consumer operators, it’s a reminder that differentiated product plus disciplined ops can clear the bar even in a choppy macro.
Startups & VentureOpenAI Leans Toward Waiting Until 2027 for IPO: NY Times
Pushing an IPO out to 2027 signals OpenAI is prioritizing strategic flexibility and regulatory navigation over near-term liquidity. For enterprises, that likely means continued aggressive reinvestment in models and infra — budget for rapid capability shifts rather than a slower, post-IPO optimization phase.
Startups & VentureAmperity hit with layoffs as AI changes the shape of the customer data startup and how it operates
Amperity cutting staff while citing AI reshaping its customer data business is a concrete example of AI compressing headcount in data-heavy SaaS. If your product overlaps with what foundation models can now do natively — unifying, segmenting, and activating data — you need a sharper wedge than “CDP with AI.”
Startups & VentureSpaceX Sale Shows Funding Across Equity, Credit: Hjort
SpaceX tapping both equity and credit markets at scale shows late-stage frontier tech is now treated as core infrastructure, not a speculative bet. For founders in capital-intensive domains, mixed-structure financing is becoming the norm, not the exception.